Navigation Links
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
Date:5/15/2008

- Safety and Efficacy Clinical Data from Prostate, Colorectal and Ovarian

Cancers - - Company to Hold Investor Event on Sun., June 1 with Oncology Experts -

SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. The Company will present preliminary data from its ongoing Phase 2 clinical trial of picoplatin in colorectal cancer (CRC) and updated data from its Phase 1 CRC trial, data from its ongoing Phase 2 trial of picoplatin in hormone refractory prostate cancer (HRPC), as well as data from a Phase 1 trial of picoplatin in advanced solid tumors, including ovarian cancer.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, administered either alone or in combination with other chemotherapy and targeted agents.

"We are continuing to execute on our clinical strategy, demonstrating that picoplatin is a platform product, with broad utility in multiple solid tumor types," said Ronald Martell, president and chief operating officer of Poniard Pharmaceuticals. "The data from these trials that we will present at ASCO should illustrate the significant clinical value of picoplatin to patients with a broad range of tumor types, including those with colorectal, prostate and ovarian cancer. These results should
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
7. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
10. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...gnostic Value of Circulating Tumor Cells, RARITAN...prospective,clinical trial found the number of cir...of progression-free and overall survival among met... report published in the July 1,issue of the Journ... the US, the Netherlands, and the United,Kingdom, ...
(Date:7/24/2008)... 24 /PRNewswire-USNewswire/ -- Headlines claiming ...hole story. The small scale,preliminary study tha...production, is based on recollected intake of soyf.... "This study is confounded by many,issues, thus I...al of,caution," warned Dr. Tammy Hedlund, a resear...
(Date:7/23/2008)...st Approved Systemic Therapy to Treat the Disease ...RNewswire-FirstCall/ --,Bayer HealthCare Pharmaceu...X) today announced that The New England Journal of...onstrating that Nexavar(R) (sorafenib),tablets dec... patients with,unresectable hepatocellular carcino...
(Date:7/23/2008)... Some Areas of the Body Have Greater Concentration... /PRNewswire-USNewswire/ -- Fat removed,from the l...as found to be,an excellent source of stem cells, ...eas of the body, reports a Brazilian-based study i...the official medical journal of the,American Socie...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Data Show Common Allergy Tests Are Not Interchangeable 18816 1Data Show Common Allergy Tests Are Not Interchangeable 18816 2Data Show Common Allergy Tests Are Not Interchangeable 18816 3Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Angiotech to participate in Bank of America Health Care Conference 5229 1Federal polar bear research critically flawed says study in INFORMS journal 3237 1Federal polar bear research critically flawed says study in INFORMS journal 3237 2
...RE)--Jun 11, 2007 - Repros,Therapeutics Inc. (Nasd...ts six month study of Proellex in the treatment of...nrolled 39,premenopausal women and has completed s... levels of Proellex(TM) as well as a,positive cont...H,agonist also known as Lupron(R) or leuprolide ac...
...Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN)...linical studies for NG2-73, the Company,s lead com...d today at the SLEEP,2007 Annual Meeting of the As...nneapolis, Minnesota. Two Phase 2b clinical studie...rently being,conducted by the Company. Data presen...
Other Medicine Technology:Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4
(Date:7/25/2008)..., N.Y., July 25 /PRNewswire-USNewswire/ -- Anthony...ality Officer and Vice President,of Strategic Plan...und, a,national foundation committed to improving ...the foundation,s Program on Health Care Quality,Im...scom.com/cgi-bin/prnh/20080725/DC28791LOGO ), Bo...
(Date:7/25/2008)...leaning products reduces lung function, increases ..., July 25 (HealthDay News) -- A clean, fresh-smell...nding on what type of cleaning and air freshening ...at exposure to cleaning products or air fresheners...(VOC) called 1,4 dicholorobenzene (1,4 DCB), can r...
(Date:7/25/2008)... Though the number of jobs created in the...anies reported a different kind of slowdown: they ...ths. , Seattle, WA (PRWEB...ed in the medical field slowed in June overall, ph...f slowdown that will be music to the ears of sales...
(Date:7/25/2008)... Corporation Executive, Robert J. Reilly, Joins Ae...thon Inc.,( http://www.aethon.com ), the leading d...ain logistics, today announced that Robert J. Reil... -- Chief Financial Officer., Reilly, who was mos...cKesson Corporation,s Specialty Pharmacy Division,...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2
...ion feels that Asia is facing an increased threat ...ur in. Dr. Shigeru Omi, Regional Director, WHO Wes... planning and working to combat bird flu spread bu...d should be done to prevent bird flu spread. It is...
...e that of viral flu are spreading across Delhi wit...Delhi recorded a minimum of 0.2 degrees Celsius (7...eek later the temperature reached 11.6 degrees //(... 2006. Doctors have called upon people to be caref...
...re exploring the possibility for using Kaiso prote...ping this new approach to treat intestinal cancer ...ciences, //under Anna Prokhorchuk's guidance joint... the international CRDF foundation and the Federal...
...Weizmann Institute of Science throws light on cell... old age. These findings appear in the February is...artz of the Neurobiology Department at Weizmann le...t implication in delaying the onset of cognitive d...
Other Medicine News:Health News:Methyl-DNA binding Proteins To Fight Cancer 2Health News:Weizmann Institute of Science says Immune Cells Could Help Maintain Brain Function 2
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: